Multivitamin Tablets Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

The multivitamin tablets project requires navigating dual regulatory jurisdictions depending on therapeutic claims. Products with disease-prevention or treatment claims fall under CDSCO purview, while nutrition-positioned products require FSSAI licensing. The manufacturing facility must comply with Schedule M (WHO-GMP) regardless of final product classification.

• CDSCO Manufacturing License (Form 27/28): Required for drug license. Application through SUGAM portal. Timeline: 90-120 days. Capacity-specific licensing for different tablet strengths.
• Schedule M Compliance: WHO-GMP standards mandatory. Requires separate quality control laboratory, environmental monitoring systems, and documentation protocols for process validation.
• FSSAI State License (Form B): Required if any product is marketed as food supplement. Central license from FSSAI for turnover exceeding ₹12 crore. License number must appear on all labels.
• BIS Certification (IS 13485): Applicable for vitamin premixes used in manufacturing. Third-party testing of raw material specifications against Bureau of Indian Standards parameters.
• GST Registration and Composition Scheme: GSTN registration mandatory. Consider composition scheme if turnover below ₹1.5 crore for reduced compliance burden.
• Pollution Control Board Consent: Consent under Water Act and Air Act. CPCB guidelines for pharmaceutical effluent treatment. CTO issued after EIA compliance assessment.
• Drug Testing Laboratory Registration: Each batch requires testing at NABL-accredited laboratory or in-house facility meeting Schedule M Part VII requirements.
• MSME Udyam Registration: Obtain for eligibility under priority sector lending. Required for CGTMSE coverage and various state government incentive schemes.

KAMRIT Financial Services LLP manages the complete licensing chain from CDSCO Form 27 applications through FSSAI state licensing, coordinating with State Drug Controllers in target states including Gujarat, Himachal Pradesh, and Maharashtra where pharmaceutical clusters offer established supply chains and workforce availability.

The multivitamin tablets segment sits at the intersection of pharmaceutical formulation and nutritional supplement markets, each governed by distinct regulatory pathways. CDSCO-regulated prescription multivitamins account for approximately 45% of market value, while FSSAI-licensed food supplement multivitamins constitute the remainder. The sports nutrition segment within multivitamins is expanding at 22% CAGR, outpacing the overall category.

Pediatric and geriatric formulations represent high-margin sub-segments growing at 19% CAGR as India's demographic structure shifts. B-complex and iron-fortified combinations dominate rural distribution channels, while multivitamin-mineral complexes with zinc and selenium lead urban retail. The D2C-first brand cohort has captured 12% of premium urban sales through subscription models, fundamentally altering channel dynamics.

Hospital procurement for IPD and OPD patient care drives separate demand streams. The family-owned legacy business segment retains 35% of institutional supply through established formulary relationships. Contract manufacturing within the segment is growing at 15% CAGR as brand owners prefer capital-light models.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3
• Telemedicine and digital health adoption

Multivitamin tablet manufacturing requires a sequential line configuration: granulation (wet or dry), blending, compression, coating, and packaging. For a 200-300 million tablet annual capacity project, a 60-72 station rotary compression machine from Korean manufacturers such as Sejong or Korean Make offers throughput of 150,000-200,000 tablets per hour with power consumption of 35-45 kW. European alternatives from Korsch orIMA offer higher automation but at 40% capital premium.

Chinese equipment from Shanghai Tianfan provides entry-level pricing but carries reliability and spare-part availability concerns for Indian pharmaceutical operations. The coating system requires a fully perforated pan coater with spray system for film coating of multivitamin tablets, adding ₹80-120 lakh to line cost. Granulation equipment from Gansons or Rimeks (Indian manufacturers) achieves adequate performance at ₹60-90 lakh versus ₹2-3 crore for equivalent European machines.

For the ₹3.5-8 crore CapEx band, a single line configuration with Indian and Korean equipment achieves competitive operating costs of ₹0.15-0.25 per tablet in conversion costs. The ₹20-44 crore investment bracket accommodates dual lines with European coating systems and automated packaging lines achieving ₹0.08-0.12 per tablet conversion costs. Energy consumption benchmarks at 180-220 kWh per million tablets for the complete line.

For the ₹3.5-8 crore project configuration, KAMRIT recommends a 70:30 debt-to-equity structure with ₹1.05-1.20 crore promoter contribution and ₹2.45-5.60 crore term loan. SIDBI's Pharma Udyog scheme offers working capital and term loan facilities at rates 25-50 basis points below market, making it the primary lender consideration for this segment. State Bank of India and Bank of Baroda maintain dedicated pharmaceutical MSME desks and offer collateral-free loans under CGTMSE for projects meeting specified criteria. For the larger ₹20-44 crore configuration, ICICI Bank and HDFC Bank's corporate banking divisions offer project finance with DSCR covenants of 1.25x minimum. The PLI scheme for bulk drugs indirectly benefits vitamin API sourcing by encouraging domestic active ingredient production, reducing import dependency over time. Working capital requirement typically at 90-120 days of projected turnover, financed through cash credit facilities at working capital limits. State incentive schemes in Gujarat and Himachal Pradesh offer SGST refunds and electricity duty exemptions for pharmaceutical units established in designated pharma parks. The cooperative federation model offers insight into channel financing structures, where distributor credit terms of 45-60 days enable channel expansion without corresponding working capital strain.

The primary risk involves regulatory classification ambiguity between CDSCO drug products and FSSAI food supplements. A product reformulated with therapeutic claims triggers reclassification, requiring additional licensing and potentially market withdrawal during transition. Mitigation involves maintaining separate production lines or batches for each classification and pre-filing product dossiers with CDSCO before commercial launch.

The second risk concerns vitamin API import dependency, with China supplying approximately 60-65% of specialty vitamin precursors. Currency fluctuation and supply chain disruptions directly impact formulation costs. The PLI scheme addresses this over a 5-7 year horizon; near-term mitigation requires supplier diversification to European and domestic sources despite higher landed costs.

Sensitivity analysis indicates that a 10% rupee depreciation increases per-unit costs by 4-6%, while API price inflation of 15% compresses margins by 250-300 basis points. The third risk involves pricing pressure from the regional Tier-2 player cohort, which has demonstrated aggressive pricing in tender-based institutional sales. Maintaining margin discipline requires focus on OTC retail and hospital channels where brand quality justifies premium positioning.

The family-owned legacy business segment has maintained pricing power through formulary relationships, suggesting institutional channel strategy should prioritize quality documentation and tender responsiveness over price competition.